MINIDIAB - Medsafe
Hypoglycaemia All sulfonylurea agents are capable of producing severe hypoglycaemia. Proper patient selection, dosage, and instructions are important to avoid …
Download MINIDIAB - Medsafe
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Amaryl® M S.R. (Glimepiride & Metformin HCI)
pk.sanofi-aventis.comtherefore be considered. The highest recommended dose per day should be 8 mg of glimepiride and 2000 mg Of metformin. Daily doses Of glimepiride Of more than 6 mg are more effective only
Hematology review - Austin Community College
www.austincc.eduMorphologic approach Microcytic anemia – MCV < 80 fl Reduced iron availability —severe iron deficiency, the anemia of chronic disease, copper deficiency Reduced heme synthesis —lead poisoning, congenital or acquired sideroblastic anemia Reduced globinproduction —thalassemicstates, other hemoglobinopathies The three most …
DRUGS TO AVOID IN G6PD DEFICIENCY - cych.org.tw
www.cych.org.twDRUGS TO AVOID IN G6PD DEFICIENCY DEFINITE RISK OF HAEMOLYSIS POSSIBLE RISK OF HAEMOLYSIS Pharmacological Class Drugs* Pharmacological Class Drugs* • ß-Naphthol
Drug, Deficiency, Avoid, Drugs to avoid in g6pd deficiency, G6pd
DATA SHEET 1 PRODUCT NAME 2 QUALITATIVE …
www.medsafe.govt.nzNew Zealand Data Sheet August 2017 Daonil - glibenclamide . daonil-ccdsv10-1-dsv7-25aug17 Page 1 . DATA SHEET 1 PRODUCT NAME . Daonil 5mg tablets
CLINICAL PHARMACOLOGY NOTES potent - …
www.mrcpass.comCLINICAL PHARMACOLOGY NOTES Bioavailability refers to absorption of the drug. Increased gastric emptying and induction of liver enzymes increases first pass metabolism and reduced
Glucose-6-Phosphate Dehydrogenase (G6PD) …
www.dh.gov.hkGlucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. What is Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency? Glucose-6-Phosphate Dehydrogenase (G6PD) is an enzyme which protects
Generic Name Chloroquine Proguanil Mefloquine …
www.janechiodini.co.ukGeneric Name Chloroquine Proguanil Mefloquine Doxycycline Atovaquone / Proguanil Dosage and administration 310mg base (2 tablets) weekly 200mg (2 tablets)